EGFR and non-small cell lung carcinoma: Osimertinib is currently approved for advanced NSCLC patients with T790M mutation, with disease progression on or after EGFR TKI therapy [16] and is recommended as a subsequent therapy (previously referred to as second-line therapy) for patients with metastatic EGFR T790M-positive NSCLC [15].